Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Hasegawa, Satoru ^a   Goto, Sae ^a   Tsuji, Hirokazu ^b   Okuno, Tatsuya ^a   Asahara, Takashi ^b   Nomoto, Koji ^b   Shibata, Akihide ^a   Fujisawa, Yoshiro ^a   Minato, Tomomi ^a   Okamoto, Akira ^c   Ohno, Kinji ^a   Hirayama, Masaaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^c AICHI UNIVERSITY OF EDUCATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; C REACTIVE PROTEIN; INTERLEUKIN 6; LEPTIN; LEVODOPA; LIPOPOLYSACCHARIDE BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ACUTE PHASE PROTEIN; BACTERIAL DNA; CARRIER PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN; RNA 16S;

AGED; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTEROIDES FRAGILIS; CLOSTRIDIUM; CLOSTRIDIUM COCCOIDES; CONTROLLED STUDY; DISEASE DURATION; DYSBIOSIS; ESCHERICHIA COLI; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; INTESTINE FLORA; LACTOBACILLUS GASSERI; MAJOR CLINICAL STUDY; MALE; MEMBRANE PERMEABILITY; METAGENOME; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BACTERIUM; BLOOD; CASE CONTROL STUDY; CONSTIPATION; FECES; GENETICS; INTESTINE MUCOSA; MICROBIOLOGY; PERMEABILITY;

ACUTE-PHASE PROTEINS; AGED; BACTERIA; CARRIER PROTEINS; CASE-CONTROL STUDIES; CONSTIPATION; DNA, BACTERIAL; DYSBIOSIS; FECES; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MEMBRANE GLYCOPROTEINS; METAGENOME; PARKINSON DISEASE; PERMEABILITY; RNA, RIBOSOMAL, 16S;

EID: 84951284320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142164     Document Type: Article

References (52)

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007; 68(5):384-6. doi: 10.1212/01.wnl.0000247740.47667.03 PMID: 17082464.
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24(2):197-211. Epub 2002/12/25. S0197458002000659 [pii]. PMID: 12498954.
3. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord. 2010; 16(2):79-84. doi: 10.1016/j.parkreldis.2009.08.007 PMID: 19846332.
4. Katzenschlager R, Lees AJ. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol. 2004; 17(4):417-23. PMID: 15247536.
5. Hirayama M, Hakusui S, Koike Y, Ito K, Kato T, Ikeda M, et al. A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1995; 53(2-3):230-4. Epub 1995/06/25. PMID: 7560760.
6. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001; 57(3):456-62. Epub 2001/08/15. PMID: 11502913.
7. Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011; 6(12):e28032. doi: 10.1371/journal.pone.0028032 PMID: 22145021; PubMed Central PMCID: PMC3228722.
8. Mitsuoka T. Intestinal flora and human health. Asia Pac J Clin Nutr. 1996; 5(1):2-9. PMID: 24394457.
9. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013; 341(6150):1241214. doi: 10.1126/science. 1241214 PMID: 24009397; PubMed Central PMCID: PMC3829625.
10. Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. 2015; 30(3):350-8. doi: 10.1002/mds. 26069 PMID: 25476529.
11. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al. Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015. doi: 10.1002/mds.26307 PMID: 26179554.
12. Fujiwara Y, Suzuki H, Yasunaga M, Sugiyama M, Ijuin M, Sakuma N, et al. Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int. 2010; 10(3):225-32. doi: 10.1111/j.1447-0594.2010.00585.x PMID: 20141536.
13. Kobayashi M, Saito S, Kobayakawa T, Deguchi Y, Costanzo RM. Cross-cultural comparison of data using the odor stick identification test for Japanese (OSIT-J). Chem Senses. 2006; 31(4):335-42. doi: 10.1093/chemse/bjj037 PMID: 16495437.
14. Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006; 15(3):237-41. PMID: 17013448.
15. Gutsmann T, Muller M, Carroll SF, MacKenzie RC, Wiese A, Seydel U. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun. 2001; 69(11):6942-50. doi: 10.1128/IAI.69.11.6942-6950.2001 PMID: 11598069; PubMed Central PMCID: PMC100074.
16. Luk GD, Bayless TM, Baylin SB. Diamine oxidase (histaminase). A circulating marker for rat intestinal mucosal maturation and integrity. J Clin Invest. 1980; 66(1):66-70. doi: 10.1172/JCI109836 PMID: 6772669; PubMed Central PMCID: PMC371506.
17. Matsuda K, Tsuji H, Asahara T, Kado Y, Nomoto K. Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription-PCR. Appl Environ Microbiol. 2007; 73(1):32-9. doi: 10. 1128/AEM.01224-06 PMID: 17071791; PubMed Central PMCID: PMC1797142.
18. Matsuda K, Tsuji H, Asahara T, Matsumoto K, Takada T, Nomoto K. Establishment of an analytical system for the human fecal microbiota, based on reverse transcription-quantitative PCR targeting of multicopy rRNA molecules. Appl Environ Microbiol. 2009; 75(7):1961-9. doi: 10.1128/AEM.01843-08 PMID: 19201979; PubMed Central PMCID: PMC2663197.
19. Sakaguchi S, Saito M, Tsuji H, Asahara T, Takata O, Fujimura J, et al. Bacterial rRNA-targeted reverse transcription-PCR used to identify pathogens responsible for fever with neutropenia. J Clin Microbiol. 2010; 48(5):1624-8. doi: 10.1128/JCM.01724-09 PMID: 20351213; PubMed Central PMCID: PMC2863901.
20. Ohigashi S, Sudo K, Kobayashi D, Takahashi O, Takahashi T, Asahara T, et al. Changes of the intestinal microbiota, short chain fatty acids, and fecal pH in patients with colorectal cancer. Dig Dis Sci. 2013; 58(6):1717-26. doi: 10.1007/s10620-012-2526-4 PMID: 23306850.
21. Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H, et al. Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes. Diabetes Care. 2014; 37(8):2343-50. doi: 10.2337/dc13-2817 PMID: 24824547.
22. Fu Y, Ito M, Fujita Y, Ichihara M, Masuda A, Suzuki Y, et al. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease. Neurosci Lett. 2009; 453(2):81-5. Epub 2009/04/10. S0304-3940(09)00183-9 [pii] doi: 10.1016/j.neulet.2009.02. 016 PMID: 19356598.
23. Fujita K, Seike T, Yutsudo N, Ohno M, Yamada H, Yamaguchi H, et al. Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. PLoS One. 2009; 4(9):e7247. PMID: 19789628. doi: 10.1371/journal.pone. 0007247
24. Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S, Hattori N. Pilot study of H2 therapy in Parkinson's disease: A randomized double-blind placebo-controlled trial. Mov Disord. 2013; 28(6):836-9. Epub 2013/02/13. doi: 10.1002/mds.25375 PMID: 23400965.
25. Vignais PM, Billoud B. Occurrence, classification, and biological function of hydrogenases: an overview. Chem Rev. 2007; 107(10):4206-72. doi: 10.1021/cr050196r PMID: 17927159.
26. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013; 136(Pt 8):2419-31. doi: 10. 1093/brain/awt192 PMID: 23884810; PubMed Central PMCID: PMC3722357.
27. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol. 2002; 249 Suppl 3:III/1-5. Epub 2003/01/17. PMID: 12528692.
28. Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2012; 27(6):709-15. doi: 10. 1002/mds.23838 PMID: 21766334.
29. Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H, et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis. 2013; 50:42-8. doi: 10.1016/j.nbd.2012.09.007 PMID: 23017648.
30. Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, et al. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014. doi: 10.1002/mds.25895 PMID: 24838182.
31. Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, Bakay RA, et al. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord. 2014; 29(8):999-1009. doi: 10.1002/mds.25736 PMID: 24898698; PubMed Central PMCID: PMC4050039.
32. Dutta G, Zhang P, Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol. 2008; 22(5):453-64. doi: 10.1111/j.1472-8206.2008. 00616.x PMID: 18710400; PubMed Central PMCID: PMC2632601.
33. Gasbarrini A, Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Ojetti V, et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis. 2007; 25(3):237-40. doi: 10.1159/000103892 PMID: 17827947.
34. Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord. 2011; 26(5):889-92. Epub 2011/04/ doi: 10.1002/mds.23566 PMID: 21520278.
35. Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord. 2013; 28(9):1241-9. doi: 10.1002/mds.25522 PMID: 23712625.
36. Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord. 2014; 20(5):535-40. Epub 2014/03/19. doi: 10.1016/j.parkreldis.2014.02.019 PMID: 24637123.
37. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006; 66(12):1824-9. doi: 10.1212/01.wnl.0000221672.01272.ba PMID: 16801644.
38. Tan AH, Mahadeva S, Marras C, Thalha AM, Kiew CK, Yeat CM, et al. Helicobacter pylori infection is associated with worse severity of Parkinson's disease. Parkinsonism Relat Disord. 2015; 21(3):221-5. Epub 2015/01/07. doi: 10.1016/j.parkreldis.2014.12.009 PMID: 25560322.
39. Baranowska B, Wasilewska-Dziubinska E, Radzikowska M, Plonowski A, Roguski K. NEuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa. Metabolism. 1997; 46(12):1384-9. PMID: 9439531.
40. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014; 505(7484):559-63. doi: 10.1038/nature12820 PMID: 24336217; PubMed Central PMCID: PMC3957428.
41. Parkinson J. An essay on the shaking palsy1817.
42. Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krogius L, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005; 100(2):373-82. PMID: 15667495.
43. Ito M, Hirayama M, Yamai K, Goto S, Ito M, Ichihara M, et al. Drinking hydrogen water and intermittent hydrogen gas exposure, but not lactulose or continuous hydrogen gas exposure, prevent 6-hydorxydopamine-induced Parkinson's disease in rats. Med Gas Res. 2012; 2(1):15. doi: 10.1186/2045-9912-2-15 PMID: 22608009; PubMed Central PMCID: PMC3407490.
44. Kajiya M, Sato K, Silva MJ, Ouhara K, Do PM, Shanmugam KT, et al. Hydrogen from intestinal bacteria is protective for Concanavalin A-induced hepatitis. Biochem Biophys Res Commun. 2009; 386(2):316-21 PMID: 19523450. doi: 10.1016/j.bbrc.2009.06.024
45. Florent C, Flourie B, Leblond A, Rautureau M, Bernier JJ, Rambaud JC. Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vivo study). J Clin Invest. 1985; 75 (2):608-13. Epub 1985/02/01. doi: 10.1172/JCI111738 PMID: 3973020; PubMed Central PMCID: PMC423537.
46. Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med. 1986; 164(3):777-93. PMID: 2427635; PubMed Central PMCID: PMC2188379.
47. Froon AH, Dentener MA, Greve JW, Ramsay G, Buurman WA. Lipopolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis. 1995; 171(5):1250-7. PMID: 7538550.
48. Schumann RR, Zweigner J. A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Clinf Chem Lab Med. 1999; 37(3):271-4. doi: 10.1515/CCLM.1999.047 PMID: 10353471.
49. Martin TR, Mathison JC, Tobias PS, Leturcq DJ, Moriarty AM, Maunder RJ, et al. Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs. J Clin Invest. 1992; 90(6):2209-19. doi: 10.1172/JCI116106 PMID: 1281827; PubMed Central PMCID: PMC443371.
50. Ding PH, Jin LJ. The role of lipopolysaccharide-binding protein in innate immunity: a revisit and its relevance to oral/periodontal health. J Periodontal Res. 2014; 49(1):1-9. doi: 10.1111/jre.12081 PMID: 23601005.
51. Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson's disease. Neuroscience. 2014. Epub 2014/12/03. doi: 10.1016/j.neuroscience.2014.10.028 PMID: 25450953.
52. Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, Chong WL, et al. Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free Radic Biol Med. 2010; 48(4):560-6. doi: 10.1016/j. freeradbiomed.2009.11.026 PMID: 19969070.